Clinical Trial Update: Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating nintedanib (BIBF1120) in patients with recurrent or metastatic salivary gland cancer of the head and neck. The current study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Salivary Gland Cancer

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck | Phase 2 | Status: UNKNOWN